p38 mitogen-activated protein kinase: Functions and targeted therapy in diseases

被引:3
作者
Zheng, Qinwen [1 ]
Li, Shutong [1 ]
Wang, Aoxue [1 ]
Zhe, Man [1 ,2 ]
Yang, Panpan [1 ]
Wu, Yongya [1 ]
Zhao, Min [1 ]
Zhu, Yumeng [1 ]
Luo, Yi [1 ,3 ]
Wang, Guan [1 ]
Ouyang, Liang [1 ]
机构
[1] Sichuan Univ, Nursing Key Lab Sichuan Prov, West China Hosp,State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr,Innovat Ctr Nursing Res, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Anim Expt Ctr, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Orthoped Res Inst, Dept Orthoped, Chengdu, Sichuan, Peoples R China
来源
MEDCOMM-ONCOLOGY | 2023年 / 2卷 / 03期
基金
中国国家自然科学基金;
关键词
anticancer; P38 mitogen-activated protein kinase (P38MAPK); small-molecule inhibitors; structure-activity relationships (SARs); P38-ALPHA MAP KINASE; AMYOTROPHIC-LATERAL-SCLEROSIS; SELECTIVE INHIBITOR; RHEUMATOID-ARTHRITIS; STRUCTURAL FEATURES; ALZHEIMERS-DISEASE; SIGNALING CASCADES; DOSE-ESCALATION; ALPHA-SYNUCLEIN; SB; 203580;
D O I
10.1002/mog2.53
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P38 mitogen-activated protein kinase (p38MAPK) is a multifunctional protein kinase that plays an important role in human normal physiological activities and a variety of major diseases, and its signaling pathway affects a variety of regulatory factors in vivo, which is related to cell cycle, survival, metabolism, and differentiation. The four subtypes of p38MAPK have significant differences in their distribution, content, and effects in the body. The inhibitors of the four subtypes play potential roles in regulating cancer, neurodegenerative diseases, inflammation, and cardiovascular diseases, making it an attractive target for drug development. So far, an increasing number of p38MAPK inhibitors have been developed for targeted therapy in diseases, among which some representative compounds have entered clinical trials. Therefore, this review aims to provide a summary of the structural characteristics, signaling pathways of P38MAPK and the relationship between p38MAPK and disease, along with an overview of the binding modes and structure-activity relationships of small molecule inhibitors targeting four p38MAPK subtypes, and summarizes the challenges about the development of p38MAPK inhibitors, hoping to provide a valuable reference for the development and application of novel inhibitors. Our review provides an overview of the relationship between P38 mitogen-activated protein kinase (p38MAPK) and disease, especially on small-molecule inhibitors of four p38MAPK subtypes, and summarizes the challenges about the development of p38MAPK inhibitors. image
引用
收藏
页数:42
相关论文
共 193 条
[1]   Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes [J].
Adams, JL ;
Boehm, JC ;
Kassis, S ;
Gorycki, PD ;
Webb, EF ;
Hall, R ;
Sorenson, M ;
Lee, JC ;
Ayrton, A ;
Griswold, DE ;
Gallagher, TF .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) :3111-3116
[2]   Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region [J].
Ahn, Yu Mi ;
Clare, Michael ;
Ensinger, Carol L. ;
Hood, Molly M. ;
Lord, John W. ;
Lu, Wei-Ping ;
Miller, David F. ;
Patt, William C. ;
Smith, Bryan D. ;
Vogeti, Lakshminarayana ;
Kaufman, Michael D. ;
Petillo, Peter A. ;
Wise, Scott C. ;
Abendroth, Jan ;
Chun, Lawrence ;
Clark, Robin ;
Feese, Michael ;
Kim, Hidong ;
Stewart, Lance ;
Flynn, Daniel L. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) :5793-5798
[3]   Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases [J].
Albrecht, Wolfgang ;
Unger, Anke ;
Bauer, Silke M. ;
Laufer, Stefan A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) :5290-5305
[4]   Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor [J].
Ali, Eslam M. H. ;
Abdel-Maksoud, Mohammed S. ;
Hassan, Rasha Mohamed ;
Mersal, Karim I. ;
Ammar, Usama M. ;
Se-In, Choi ;
He-Soo, Han ;
Kim, Hee-Kwon ;
Lee, Anna ;
Lee, Kyung-Tae ;
Oh, Chang-Hyun .
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 31
[5]   Versatile three component coupling for the synthesis of pyrazolopyridines and other pyrido fused systems [J].
Almansa, Carmen ;
Virgili, Marina ;
Carceller, Elena ;
Grima-Poveda, Pedro .
HETEROCYCLES, 2008, 75 (07) :1695-1709
[6]   A Special View of What Was Almost Forgotten: p38δ MAPK [J].
Anton, Debora Bublitz ;
Ducati, Rodrigo Gay ;
Timmers, Luis Fernando Saraiva Macedo ;
Laufer, Stefan ;
Goettert, Marcia Ines .
CANCERS, 2021, 13 (09)
[7]   Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation [J].
Antoon, James W. ;
Bratton, Melyssa R. ;
Guillot, Lori M. ;
Wadsworth, Scott ;
Salvo, Virgilio A. ;
Burow, Matthew E. .
CANCER BIOLOGY & THERAPY, 2012, 13 (11) :1026-1033
[8]  
Antoon JW, 2012, AM J CANCER RES, V2, P446
[9]   Design and synthesis of novel p38α MAP kinase inhibitors: Discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety [J].
Arai, Tadamasa ;
Ohno, Michihiro ;
Inoue, Hideki ;
Hayashi, Shinnosuke ;
Aoki, Takumi ;
Hirokawa, Hiroe ;
Meguro, Hiroyuki ;
Koga, Yoko ;
Oshida, Keiyu ;
Kainoh, Mie ;
Suyama, Kazuharu ;
Kawai, Hideki .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (15) :5118-5122
[10]  
Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453